Quantcast

Latest Antibody Stories

2014-04-07 04:21:25

BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ -- New findings to be presented at the American Association for Cancer Research annual meeting arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody(TM) platform has identified four 'hotspots' on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET...

2014-04-03 16:23:53

AUSTIN, Texas, April 3, 2014 /PRNewswire/ -- XBiotech announced today that it acquired the patent estate of Strox Biopharmaceuticals relating to antibody therapies for methicillin resistant staphylococcus aureus (MRSA). XBiotech is developing next generation natural immune therapies to address serious and drug resistant bacterial infections. The in-licensed technology is reportedly intended to expand and strengthen XBiotech's position for its infectious disease product development...

2014-04-03 12:28:49

TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, Denmark for the development of companion diagnostic tools for Genmab's HuMax-TF®-ADC antibody drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the...

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-04-03 08:22:27

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/gw6znv/the_engineered ) has announced the addition of the "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective...

2014-04-01 23:26:14

Xtalks presents a new webinar on Wednesday, April 23, 2014 at 11:00 EDT (16:00 UK BST/ GMT +1). Join Dr. Dhaval Shah, Assistant Professor, Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, for a one-hour live presentation. Toronto, Canada (PRWEB) April 01, 2014 Antibody Drug Conjugates (ADCs) are at the forefront of the therapeutic market. The first therapeutic antibody was approved by the U.S. Food and Drug Administration (FDA) in 1986. Since...

2014-03-31 08:31:02

SAN FRANCISCO and WALTHAM, Mass., March 31, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these...

2014-03-28 08:26:41

MONROVIA, Calif., March 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific antibody programs at the Annual Summit on Practical and Emerging Trends in Multiple Myeloma being held in Whistler, British Columbia, Canada. The discussion featured Xencor's bispecific approach...

2014-03-25 08:30:28

ROCKVILLE, Md., March 25, 2014 /PRNewswire/ -- VLP Therapeutics, Inc. ("VLP"), a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i- VLP technology (which stands for "inserted alpha virus like particle"), today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of...

2014-03-24 08:29:41

SAN FRANCISCO, March 24, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it will present at the 21(st) Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City. William J. Newell, chief executive officer of...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related